The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. - Test2 - elhamkhani - TriplyDB

The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model.

The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model.

http://www.wikidata.org/entity/Q35072606

about

Combination therapy for inflammatory bowel disease Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.Combination therapy for the treatment of Crohn's disease.Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study.Positioning Therapy for Ulcerative Colitis.Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.Recent advances in understanding and managing Crohn's disease.Cost-utility Analysis: Thiopurines Plus Endoscopy-guided Biological Step-up Therapy is the Optimal Management of Postoperative Crohn's Disease.

P2860

Q33646452-FFBDAF4D-4F05-46DF-BA34-2898D30EF279 Q34520662-03E08090-C8B3-419C-A3D2-53FAA3CF2708 Q35714202-D2C0B5DB-9467-43EC-919C-572C68689265 Q37047522-3175DD66-F3FE-44B3-B35E-05F0CFD0FD95 Q38542903-68FB3A06-0FE1-4777-836F-28319F4EDC1D Q38735146-14732FA2-1850-4EB1-84AF-C6EA5FDCA539 Q39121157-43666498-FD98-4365-8704-6A863F702D4F Q48530814-A96F3102-C037-4447-AF84-EB60C6992FBE

P2860

The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model.

http://www.wikidata.org/entity/Q35072606

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The benefit-to-risk balance of ...... ries with age: a markov model.

@ast

The benefit-to-risk balance of ...... ries with age: a markov model.

@en

type

label

The benefit-to-risk balance of ...... ries with age: a markov model.

@ast

The benefit-to-risk balance of ...... ries with age: a markov model.

@en

prefLabel

The benefit-to-risk balance of ...... ries with age: a markov model.

@ast

The benefit-to-risk balance of ...... ries with age: a markov model.

@en

P1433

Q35072606-6289D53F-D289-4F04-8E4E-EFCF2364ED8A

P1476

Q35072606-AE7237E9-8AAE-46F2-ADCA-A732B41707DA

P2093

Q35072606-21BFE418-5AD5-411C-A435-C2DB0D88C373

Q35072606-585F2A66-B56C-4DDE-996A-4E38B3D2D73A

Q35072606-5BD9F438-9660-4835-BC46-E9A2BD32415B

Q35072606-64843754-3266-4FA2-A4DF-230CFCB1901F

Q35072606-B6625ECA-DE8C-4D9A-BDA0-1FFB741DF435

P2860

Q35072606-0070739A-5B71-4515-BF25-457B4B9F29CE

Q35072606-19C4BA15-2BA6-4A1F-BC42-486AF44F8A30

Q35072606-2292AB2C-92BD-4E5B-B3A8-2597CCB71819

Q35072606-2747857A-218E-4253-A05F-8EC68B8D4EFA

Q35072606-2EB89AF0-86CF-4E53-96B2-87610AFFAFB8

Q35072606-2FD9E7BB-9A91-4F12-B3AB-BE6D1AD57BA3

Q35072606-3CAD517A-35B5-4674-A096-103DE5BFA62F

Q35072606-59521C75-5253-492F-80E3-DBF07ABE4165

Q35072606-6B9D4BDA-C737-4890-BB43-AE79EC7CC818

Q35072606-71A74997-578A-4FC1-8581-535E8478EAC7

P304

Q35072606-843A341E-74CF-4040-8B52-78D64784941E

P31

Q35072606-3F4C5E49-594D-4035-ABEC-9DA34BEC1E7D

P356

Q35072606-44943213-BBDC-470A-A17B-C3D75CB1F9DF

P407

Q35072606-1ED7B2E2-002C-46BD-863A-A5907EC14399

P433

Q35072606-117D95BF-DDF4-4EBD-A167-B63A0980F6D0

P478

Q35072606-440F84FB-C557-42B0-96A9-470ABD22E5A6

P50

Q35072606-4AA26709-7B01-4D1D-81C6-4AD4FB159FF2

Q35072606-767F008D-AE31-4322-A959-F7B24E195357

P577

Q35072606-2801BDB8-CF5F-44F7-8856-6E8E239E101A

P698

Q35072606-3C22E1E9-546D-4B0C-84D4-590B99FF39B5

P932

Q35072606-6D0D8251-BADB-47C0-AD99-36C053643A0B

P356

J.CGH.2014.07.058

P1433

Clinical Gastroenterology and Hepatology

P1476

The benefit-to-risk balance of ...... ries with age: a markov model.

@en

P2093

David S Goldberg

http://www.w3.org/2001/XMLSchema#string

James D Lewis

http://www.w3.org/2001/XMLSchema#string

Meenakshi Bewtra

http://www.w3.org/2001/XMLSchema#string

Ravy K Vajravelu

http://www.w3.org/2001/XMLSchema#string

Ronac Mamtani

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease

Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease

Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease.

Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis

Predictive factors of early bowel obstruction in colon and rectal surgery: data from the Nationwide Inpatient Sample, 2006-2008.

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

Increased risk of pneumonia among patients with inflammatory bowel disease.

The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006.

P304

302-309.e11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CGH.2014.07.058

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25117775

http://www.w3.org/2001/XMLSchema#string

P932

4324381

http://www.w3.org/2001/XMLSchema#string